Silence Therapeutics plc announces changes in leadership effective 14 December 2025.
Craig Tooman, CEO and Board member since 2022, agreed to end his employment with the Company by mutual consent.
James Ede Golightly, a former Non-Executive Director, re-appointed to the Board of Directors.
Leadership Changes
Craig Tooman's departure leads to Iain Ross taking over as Chairman on an interim basis.
Strategic Move
Anticipation of further commercial and scientific advancements with the pipeline.
Board Expansion
Appointment of a US-based Board member expected in the future.
- Silence Therapeutics shows financial and operational robustness post the leadership changes.
- Focus on areas of high unmet medical need persists with programs advancing in cardiovascular disease, hematology, and rare diseases.
Silence Therapeutics remains committed to transforming lives through precision engineered medicines, leveraging its siRNA technology.